Assignee: Genetics Institute, L.L.C.

Location: Cambridge, MA
No. of patents: 23

Browse patents
Browse applications

Number	Title	Issue Date
7460961	N-TRADD active site and uses thereof The present invention relates to the three dimensional solution structure of the N-terminal domain of TNFR-1 associated death domain protein (“N-TRADD”), as well as the identification and characterization of a C-TRAF2 binding active site of N-TRADD. Also provide...	12/02/2008
7459544	Nucleic acids encoding B7-2 fusion proteins Nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the nucleic acid has a sequence which encodes a B lymphocyte antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a por...	12/02/2008
7459533	Human GIL-19/AE289 proteins Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed. ...	12/02/2008
7432059	Methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1 mediated signal The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors contain...	10/07/2008
7405272	Selectin ligand interactor cytoplasmic (SLIC-1), a P-selectin glycoprotein ligand (PSGL-1) binding protein The invention provides isolated nucleic acids molecules, designated SLIC-1 nucleic acid molecules, which encode novel P-selectin glycoprotein ligand (PSGL-1) binding molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vect...	07/29/2008
7396911	Chimeric polypeptides containing chemokine domains This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof. ...	07/08/2008
7378392	Bone and cartilage inductive proteins Purified cartilage and/or bone inductive proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair. ...	05/27/2008
7365052	Tendon-inducing methods Compositions of proteins with tendon/ligament-like tissue inducing activity are disclosed. The compositions are useful in the treatment of tendinitis and tendon or ligament defects and in related tissue repair. ...	04/29/2008
7323445	Methods and compositions for healing and repair of articular cartilage Methods and compositions are provided for the treatment of articular cartilage defects and disease involving the combination of tissue, such as osteochondral grafts, with active growth factor. The active growth factor is preferably a composition containing at least ...	01/29/2008
7307161	Human Gil-19/AE289 polynucleotides Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed. ...	12/11/2007
7300772	BMP products Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair. ...	11/27/2007
7279559	Antibodies that bind to interleukin-22 Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders. ...	10/09/2007
7252820	Highly purified mocarhagin, a cobra venom protease, polynucleotides encoding same and related proteases, and therapeutic uses thereof Methods and compositions for treating a wide range of inflammatory diseases and disorders, and for inhibiting selectin-mediated binding by administering a mocarhagin protein, or fragments thereof with mocarhagin protein activity are provided. The mocarhagin protein ...	08/07/2007
7235367	Method using crystal structure of estrogen receptor-β complex This invention is directed to the crystal structure of Estrogen Receptor-β (ER-β) complexed with genistein, and to the use of this structure in rational drug design methods to identify agents that may interact with active sites of ER-β, which may be useful as nov...	06/26/2007
7232566	Methods for treating HIV infected subjects Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the...	06/19/2007
7223848	Methods for purifying Fc-containing proteins The present invention provides a process for dissociating Fc-containing molecules from complexes of Protein A/Fc-containing molecules or mixtures containing Fc-containing molecules and Protein A. The association, e.g., by hydrophobic interactions, between the Fc-con...	05/29/2007
7217691	Methods of treatment of periodontal disease Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair. ...	05/15/2007
7198789	Methods and compositions for modulating interleukin-21 receptor activity Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in v...	04/03/2007
7189400	Methods of treatment with antagonists of MU-1 Provided is a method of suppressing an immune response in a subject by administering an antagonist of a MU-1 hematopoietin receptor superfamily chain protein. ...	03/13/2007
7189392	Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins An injectable formulation is disclosed for delivery of osteogenic proteins. The formulation comprises a pharmaceutically acceptable admixture of an osteogenic protein; and formulations comprising osteogenic protein, hyaluronic acid derivatives and tricalcium phospha...	03/13/2007
7175997	BMP-11 compositions Purified BMP-11 proteins and processes for producing them are disclosed. Recombinant DNA molecules encoding the BMP-11 proteins are also disclosed. The proteins may be useful in regulating follicle stimulating hormone, such as for contraception. In addition, the pro...	02/13/2007
6858421	Cytosolic phospholipase A2-beta enzymes The invention provides a novel calcium-independent cytosolic phospholipase A2-Beta enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade. ...	02/22/2005
6482625	Cytosolic phospholipase A2-beta enzymes The invention provides a novel calcium-independent cytosolic phospholipase A2 -Beta enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade...	11/19/2002

PatentStorm

Quotables

PatentStorm News

Assignee: Genetics Institute, L.L.C.